Unique ID issued by UMIN | UMIN000032320 |
---|---|
Receipt number | R000036844 |
Scientific Title | Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies. |
Date of disclosure of the study information | 2018/04/20 |
Last modified on | 2018/04/19 18:11:26 |
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.
Lotriga Residual Risk Reduction Trial
LR3 Trial
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.
Lotriga Residual Risk Reduction Trial
LR3 Trial
Japan |
The subjects with hyper-triglyceridemia and atherosclerosis.
Medicine in general | Cardiology | Endocrinology and Metabolism |
Others
NO
The purposes of current study entitled, Lotriga Residual Risk Reduction Trial, is to elucidate the unknown relationships among hypertriglyceridemia, commensal microbes and auto-antibodies for development and progression of human atherosclerosis.
Efficacy
Exploratory
Explanatory
Phase II
Primary Objectives: Changes of serum TG(triglyceride) concentrations, fatty acids four fractions before, during, and after clinical trials as for indexes of pharmaceutical efficacy.
Secondary Objectives:
Changes of fecal commensal microbiota. (T-RFLP), fecal IgA, fecal mucin for feces. Changes of serum auto-antibodies (anti-IL5), total IgG, IgG3.
Changes of gene expressions of peripheral mononuclear cells. (RT-PCR)
Changes of structural, functional markers for atherosclerosis.
(cervical US, API/AVI).
Occurrences of major adverse cardiovascular events. (MACE)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
Institution is not considered as adjustment factor.
NO
No need to know
1
Treatment
Medicine |
For study participants, 2 g once a day as omega-3 fatty acid ethylate, Lotriga, is administered in the morning immediately after meals.
20 | years-old | < |
Not applicable |
Male and Female
Inclusion Criteria
The subjects who are following criteria are enrolled for the study; age >20 years old, subjects with hyper-triglyceridemia and fasting triglyceride >150mg/dl, subjects with ischemic heart disease (IHD) under current treatment or with history of IHD or subjects with cervical atherosclerosis (ccIMT>1.1mm) or subjects with PAD defined as ABI<0.9, subjects who agree with informed consent by practitioner at enrollment.
Exclusion criteria are as follows:
1. Patients in whom Lotriga is contraindicated such as patients with a history of hypersensitivity to any ingredient of Lotriga or other omega-3 unsaturated fat, and patients who are bleeding with following conditions; hemophilia, capillary fragility disease, gastrointestinal ulcer, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.
2. Patients with active infection or malignancies
3. Pregnant women, lactating women, and patients who wish to become pregnant
4. Patients who have not provided consent to participate in the study
5. Subjects with active inflammatory diseases or active malignant tumor.
6. Subjects who are already given other omega-3 unsaturated fat regimen.
7. Subjects who are already given other anti-hypertriglyceride medication such as fibrate derivatives, nicotinic acids derivatives. (Subjects who are already given statins are not excluded from participants.)
8. Subjects who are not in consent with research protocol.
Furthermore, patients who meet the following criteria will be excluded:
1. Patients with symptomatic heart failure (NYHA class 2 or higher or EF < 40%)
2. Patients with possible type 1 diabetes mellitus
3. Patients who are scheduled to undergo coronary revascularization
(Patients who underwent percutaneous transluminal coronary angioplasty including drug-eluting stent placement may be enrolled.)
4. Patients with serious liver or renal disorder
5. Patients who are determined to be not suitable by the investigator for reasons other than the above.
36
1st name | |
Middle name | |
Last name | Tomoaki Ishigami |
Yokohama City University Graduate School of Medicine
Department of Medical Science and Cardio-Renal Medicine
3-9, Fukuura, Kanazawa-ku, YOKOHAMA
045-787-2635
tommmish@hotmail.com
1st name | |
Middle name | |
Last name | Kentaro Arakawa |
Yokohama City University Hospital
Laboratory Medicine
3-9, Fukuura, Kanazawa-ku, YOKOHAMA
045-787-2635
hiroking@gamma.ocn.ne.jp
Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine
Yokohama City University Graduate School of Medicine
Self funding
NO
公立大学法人横浜市立大学附属病院
2018 | Year | 04 | Month | 20 | Day |
Unpublished
Preinitiation
2018 | Year | 03 | Month | 05 | Day |
2018 | Year | 04 | Month | 01 | Day |
2018 | Year | 04 | Month | 19 | Day |
2018 | Year | 04 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036844
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |